Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausa... (led Phase 3 study that evaluated 3397 he...)

HOME >> MEDICINE >> TECHNOLOGY

Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms

Date:7/27/2009

led Phase 3 study that evaluated 3,397 healthy, postmenopausal women with an intact uterus aged 40 to 75 years. The primary end point of the SMART-1 trial was incidence of endometrial hyperplasia at one year. Secondary end points included bone mineral density (BMD) at two years, menopausal vasomotor symptoms at four and 12 weeks, vaginal maturation index at six months, menopause-related quality of life measures, and overall safety and tolerability. The results were published concurrently across four manuscripts at http://www.fertstert.org/inpress.

Titles and Summary of Findings From Published Manuscripts

1. Endometrial Protection in Menopausal Therapy with a Tissue Selective Estrogen Complex (TSEC) Containing Bazedoxifene/Conjugated Estrogens (Pickar JH, et al)

To evaluate endometrial effects, biopsies were performed at screening and at months six, 12, and 24, or when subjects withdrew from the study and more than three months had elapsed since their last assessment. Treatment with BZA/CE doses being considered for therapeutic use were associated with rates of endometrial hyperplasia <1%. These rates were not significantly different from those reported with placebo over two years of study.

2. Bazedoxifene/Conjugated Estrogens (BZA/CE): Incidence of Uterine Bleeding in Postmenopausal Women (Archer DF, et al)

To evaluate the effect of treatment with BZA/CE on uterine bleeding, trial participants were asked to record in a diary whether or not they experienced bleeding and/or spotting. The mean number of bleeding or spotting days with BZA/CE was not statistically different from placebo over two years of therapy.

3. Evaluation of Bazedoxifene/Conjugated Estrogens (BZA/CE) for the Treatment
'/>"/>

SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
3. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
4. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
5. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
6. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
9. Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
10. Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
11. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia

Post Your Comments:

(Date:5/23/2013)... May 23, 2013 Nephros, Inc. (OTC Bulletin ... device company that develops and sells high performance liquid ... rights offering. In addition, the concurrent temporary reduction in ... on May 17, 2013. Nephros estimates that ... the rights offering. A portion of the proceeds will ...

(Date:5/23/2013)... -- A recently published clinical study conducted at TOPS Comprehensive ... demonstrates that 3D mammography (breast tomosynthesis) significantly reduces unnecessary ... The study, "Implementation of Breast Tomosynthesis in a Routine ... Stephen L. Rose , MD, and published ... of Roentgenology (AJR). The AJR is the scientific ...

(Date:5/23/2013)... , May 23, 2013 More than half ... not benefit from chemotherapy and still have excellent outcomes. ... of one of the largest sources of online consumer ... and interactive Facebook page provide recently diagnosed women with ... safely avoid chemotherapy. "We anticipate these innovative ...

Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2 Nephros Announces Completion of Rights Offering 3 Nephros Announces Completion of Rights Offering 4 First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2 First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3 Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2 Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3

[0] Nephros Announces Completion of Rights Offering [0] First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams [0] Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions

... Mass. , May 5 LightLab Imaging, ... Optical Coherence Tomography (OCT) technology for vascular and other ... and Drug Administration (FDA) for the C7-XR Imaging System ... LightLab,s latest generation Frequency Domain OCT (FD-OCT™) technology, are ...

... May 5 Zimmer Holdings, Inc. (NYSE: ZMH ; SIX: ZMH) ... Care Conference in New York, New York , on May 11, 2010 , ... , , A live ... . The webcast will be archived for replay following the conference. , ...

Cached Medicine Technology:LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 2 LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 3 LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 4 Zimmer Holdings to Present at Bank of America Merrill Lynch 2010 Health Care Conference 2

LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States Zimmer Holdings to Present at Bank of America Merrill Lynch 2010 Health Care Conference

(Date:5/25/2013)... York (PRWEB) May 25, 2013 ... litigation underway in U.S. District Court, Western District of ... According to a Case Management Order issued on ... the filing of contested motions in the Actos bladder ... motions. (In re: Actos Product Liability Litigation, MDL No. ...

(Date:5/25/2013)... May 25, 2013 Studies from Johns ... are carrying excessive weight and their inability to get ... simply losing weight can naturally relieve many symptoms. ... improvement in sleep quality was significantly associated with overall ... study dated November 6th, 2012, researchers monitored ...

(Date:5/25/2013)... (PRWEB) May 25, 2013 The ... ranging from irritable bowel syndrome (IBS) to bloating, ... among the most long-lasting, embarrassing, frustrating and difficult ... foods for digestive health have provided a ... are many factors contributing to digestive health issues, ...

(Date:5/25/2013)... (PRWEB) May 25, 2013 Dr. Farooq ... surgery clinic in Dubai, has announced his practice’s adoption ... is the only FDA-cleared femtosecond laser proven with more ... safety and precision of LASIK. , “We are happy ... Advanced Femtosecond Laser at our Dubai LASIK practice,” Ashraf ...

(Date:5/25/2013)... Prairie Living at Chautauqua , ... American Red Cross Blood Drive from 1:30 to 5:30 ... is located at 955 Villa Ct. in Carbondale, Illinois, ... Medicaid, who need some help to maintain their independence.. ... Andrea Arview Frey, Director of Marketing for Prairie Living. ...

Breaking Medicine News(10 mins):Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2 Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3 Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2 Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2 Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2 Health News:Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive 2

[0] Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation [0] hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep [0] Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org [0] Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method [0] Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive

... New York Health AdvisoryNEW YORK, Feb. 12 Asthma ... in New York City, according to the United States ... suggests that there are many causes for asthma attacks, ... system changes that result from the presence, or lack ...

... Non-attorney Representation Services , ... Belleville, Ill. (PRWEB) February ... can increase their changes of getting awarded when they hire representation, ... the Social Security Disability Insurance (SSDI) process each year. ...

... doctors, nurses, and other medical personnel wear scrubs in the ... and ties to work. What we wear, as we ... comfortable, all the while maintaining our professionalism. With all ... someone go about making an important decision such as which ...

... has been enormous public controversy over the piece published ... stimulus bill. Betsy McCaughey, Ph.D. states:1) While ... Coordinator of Health Information Technology was created by former ... for doctors and hospitals that voluntarily adopted electronic medical ...

... RUTHERFORD, N.J., Feb. 11 Cambrex Corporation (NYSE: CBM ... period ended December 31, 2008., , ... quarter 2007 and full year sales decreased 3.7% excluding the impact ... for the quarter and year, respectively. , ...

... and MTA: CTIC) announced today that the Borsa Italiana, ... Company,s common stock on the MTA stock,market in Milan, ... on February 10th. As a result of the ... additionally been halted on the NASDAQ Stock Market,pursuant to ...

Home Care Tips for Reducing the Risk of Childhood Hospitalizations Due to Asthma Social Security Disability Applicants Increase Chances for Benefits with Representation So Many Nursing Scrubs, So Many Decisions: blue sky scrubs Offers Tips on How to Find That Perfect Set of Medical Scrubs Betsy McCaughey Responds to Poorly Informed Critics Cambrex Reports Fourth Quarter and Full Year 2008 Results Cell Therapeutics Updates Shareholders on Trading

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Pb, Urine Parvovirus B19 Antibody, IgM Parvovirus B19 Antibodies, IgG & IgM Partial Thromboplastin Time with Reflex to PTT 1:1 Mix